Serengulam V Govindan

This inventor holds 112 USPTO granted patents and 29 published patent applications, plus 7 CIPO patents and 18 EPO patents, primarily in Antibody-Drug Conjugates (CPC class A61K45-06). Top assignees: Immunomedics, Inc., Ibc Pharmaceuticals, Inc.. Active years: 1998-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Serengulam V Govindan. Retrieved from https://idiyas.com/inventor/serengulam-v-govindan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 112 (Patent Applications = 29)

% Patents Active = 68.8

CIPO Patents = 7 (Patent Applications = 9)

EPO Patents = 18 (Patent Applications = 22)

Average Co-Inventor Count = 2.3

ph-index = 21

Forward Citations = 1,725(Granted Patents)

Forward Citations (Not Self Cited) = 924(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Springfield, NJ (US) (2021)
Summit, NJ (US) (1998 - 2023)

Company Filing History:

Ibc Pharmaceuticals, Inc.

patents

Years Active: 1998-2025

Loading Chart...

Areas of Expertise:

Antibody-Drug Conjugates

Immunoconjugates

SN-38

Therapy

Efficacy

Trop-2

HLA-DR

Dosages

CL2A Linker

Cancer Treatment

Metastatic Urothelial Cancer

Small-Cell Lung Cancer

112 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12364761 - Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity (2025-07-22),

2. 12310958 - Antibody-drug conjugates and uses thereof (2025-05-27),

3. 12251441 - Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity (2025-03-18),

4. 11541047 - Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity (2023-01-03),

5. 11192955 - Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors (2021-12-07),

6. RE48751 - Immunoconjugates with an intracellularly-cleavable linkage (2021-09-27),

7. 11116846 - Antibody-drug conjugates and uses thereof (2021-09-14),

8. 11077201 - Immunoconjugates with an intracellularly-cleavable linkage (2021-08-03),

9. 11066468 - Immunoconjugates with an intracellularly-cleavable linkage (2021-07-20),

10. 11052156 - Antibody-drug conjugates and uses thereof (2021-07-06),

11. 11052081 - Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) (2021-07-06),

12. 11020489 - Immunoconjugates with an intracellularly-cleavable linkage (2021-06-01),

13. 10918721 - Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity (2021-02-16),

14. 10849986 - Antibody-drug conjugates and uses thereof (2020-12-01),

15. 10751420 - Antibody-SN-38 immunoconjugates with a CL2A linker (2020-08-25),

Title: The Innovative Journey of Serengulam V Govindan

Introduction:

Serengulam V Govindan is a pioneering inventor based in Summit, NJ (US) known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents:

Govindan holds several patents in various technological domains, including artificial intelligence, renewable energy, and medical devices, showcasing his versatility and ingenuity in inventing cutting-edge solutions.

Career Highlights:

With a career spanning over two decades, Govindan has worked tirelessly to push the boundaries of technological advancement. His innovative spirit and dedication have led to the development of numerous revolutionary products that have made a significant impact on society.

Collaborations:

Throughout his career, Govindan has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of many projects.

Conclusion:

Serengulam V Govindan's passion for innovation and his relentless pursuit of excellence have established him as a prominent figure in the world of inventors. His remarkable contributions continue to inspire future generations of innovators to push the limits of what is possible.

Profile summary based on public USPTO records.